116 results about "Carbohydrate antigen" patented technology

The invention discloses an integral detecting reacting board and protein chip agent box of Carcinoembryonic antigen,CEA, 15-3 CA15-3(Carbohydrate Antigen 15-3,CA15-3), CA 125 (Cancer antigen 125,CA125), Squamous cell carcinoma antigen,SCC, Human papillomavirus antibody,HPVAb, beta-human chorionic gonadotropin, beta-HCG and alpha-fetoprotein,AFP, wherein the reacting hole board contains base and reacting hole on the base; the reacting hole contains 2-384 sample holes, 2-200 standard sample holes; the fixing phase carrier is set on the bottom of each reacting hole, which is covered by seven antigen or antibody molecule arrays with anti-CEA, anti-CA15-3,anti-CA125,anti-SCC,HPV,anti- beta-HCG,anti-AFP.

The present invention inter alia pertains to therapeutic methods which are based on the use of an agent specifically binding a tumor-associated carbohydrate antigen for the treatment of cancer stem cells and related diseases. Also provided are diagnostic and prognostic methods using a tumor-associated carbohydrate antigen as marker for cancer stem cells.

The invention relates to a magnetic corpuscule chemiluminescent enzyme immunoassay kit for detecting carbohydrate antigen and the application method thereof. The kit comprises FITC antibody-coated magnetic corpuscules; a marker solution prepared by mixing the FITC-marked carbohydrate antigen monoclonal antibody and the enzyme-marked carbohydrate antigen monoclonal antibody; a carbohydrate antigen standard sample solution; a concentrated washing solution; and a luminescent substrate solution, wherein carbohydrate antigen optionally adopts one of CA72-4, CA50, CA19-9, CA242, CA15-3, CA27-29 and CA125. The enzyme-marked antibody and the FITC-marked antibody are the monoclonal antibodies corresponding to the antigens. The FITC antibody coating the magnetic corpuscules adopts a polyclonal antibody or a monoclonal antibody. The marker solution is prepared by mixing an FITC-marked capture antibody working solution and an enzyme-marked antibody pair working solution by the volume ratio of 1:(1-3). Compared with the known kit for mensurating the carbohydrate antigen, the kit has the advantages of high flux, high sensitivity, wide linear range, rapidness, etc., and has a wide application prospect for the clinical inspection, etc.

A novel carbohydrate antigen, β1,4-GalNAc-disialyl-Lc₄, defined by monoclonal antibody RM2, is expressed in human prostate cancer, but not in benign prostate hypertrophy (BPH) or normal prostate gland. Monoclonal antibody RM2 or other antibodies with similar specificity are useful for diagnosis of prostate cancer by immunohistology of biopsy samples, specifications from a total prostatectomy, and quantitative determination of RM2 antigen in sera of patients.

The present invention provides an SPR system and corresponding methods of use, for determining the presence or concentration of tumor-associated antigens in cancer patient samples. The SPR system may have multiple channels, with each channel having operably affixed thereto an antibody specific for a tumor-associated antigen, so as to allow detection of multiple tumor-associated antigens simultaneously. When a biological sample from a patient is applied to the SPR system, the presence of two or more tumor-associated antigens can be determined by measuring an SPR signal shift from each channel. The SPR system may detect the presence or concentration of a tumor-associated carbohydrate antigen, where the sensor surface contains affixed thereto an antibody specific for the glycosyl epitope, as well as an antibody specific for the polypeptide to which the carbohydrate antigen is naturally associated in cancer patients.

The present invention relates in general to the field of cancer diagnostics and treatment. In particular, the present invention provides methods for identifying diagnostic and therapeutic molecules that bind to a carbohydrate antigen on the surface of a cancer cell and induce cell death, to pharmaceutical compositions comprising the molecules and uses thereof.

The present invention provides multi-antigenic constructs comprising one or more carbohydrate antigens having the formula:

• • wherein R¹, R^2A, R^2B, R³, R⁴, W¹, W² and W³ are as defined herein; and additionally provides compositions thereof, and methods for their use in the treatment and/or prevention of HIV infection, and methods for inducing HIV-specific antibodies in a subject, comprising administering to a subject in need thereof, an effective amount of any of the inventive compounds as disclosed herein, either in conjugated form or unconjugated and in combination with a suitable immunogenic carrier. In another aspect, the invention provides an antibody or antibody fragment which binds specifically to a gp120 glycan or glycopeptide of the invention.

The invention discloses a carbohydrate antigen 19-9 (CA 19-9) quantitative assay kit, which comprises a CA 19-9 calibration material, a CA 9-19 quality control material, an anti-reagent, a magnetic micro particle reagent, and a luminescent substrate. The invention also discloses a preparation method of the kit and a method using the kit to detect the carbohydrate antigen 19-9 (CA 19-9). Fluorescein isothiocyanate labeled CA 19-9 coated antibody and alkaline phosphatase labeled CA 19-9 labeled antibody are used to prepare the anti-reagent; anti-fluorescein isothiocyanate antibody is coupled to carboxyl magnetic beads to prepare the magnetic micro particle reagent, thus the materials can be more easily mixed and separated in immunity reactions, moreover, the reaction speed is greatly increased; a novel chemical luminescent substrate APLS is taken as the substrate, and the sensitivity and specificity of the kit are both improved. The provided kit has the advantages of high detection sensitivity, good specificity, and little variation, and the shelf life is one year or more.

The invention relates to a conjugate of monophosphate A (MPLA) and carbohydrate antigen Globo H and capable of serving as an antitumor vaccine and a preparation method and application thereof. The conjugate can be prepared through a chemical method and has the advantages of definite structure, clear composition and adjuvant needlessness. In addition, the invention further provides the applicationof the conjugate in preparing drug for treating or preventing cancer.

The invention discloses a Thomsen-Friedenreich (TF) antigen and a TF antigen analogue and their chemoenzymatic synthesis method and use. The chemoenzymatic synthesis method comprises the following steps of 1, carrying out chemosynthesis of fluorogalactose and a fluoro-galactosamine analogue, 2, carrying out enzymatic synthesis of a fluoro-TF antigen, and 3, carrying out enzymatic synthesis of a sialyl TF antigen. The preparation method has flexibility of a chemosynthesis method, and high regioselectivity and high efficiency of an enzymatic synthesis method, creatively realizes enzymatic synthesis of the fluoro-TF antigen, and solves the problem that the existing fluoro-TF antigen chemosynthesis method has low substrate reactivity, complex synthesis steps and a low yield. A tumor-associated fluoro-carbohydrate antigen is superior to a natural carbohydrate antigen in pharmacokinetic properties and thus the preparation method has wide application prospects in development of a novel anti-tumor vaccine.

The invention discloses a stomach cancer serological detection and identification kit and a method. The stomach cancer serological detection and identification kit is prepared from a cel-miR-39-5p fragment, a primer, an exosome isolating reagent, an exosome miRNA (Micro Ribonucleic Acid) extracting reagent, a reverse transcription reagent and a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) reagent, wherein the primer comprises a cel-miR-39-5p internal reference primer, an hsa-miR-375 primer, an hsa-miR-590-5p primer, an hsa-miR-19b-3p primer, an hsa-miR-100-5p primer and an hsa-miR-16 primer. When any results of detecting stomach cancer CA (Carbohydrate Antigen)19-9, CA24-2 and CEA (Carcino Embryonie Antigen) of a patient by using serum are positive, and the stomach cancer serological detection and identification kit provided by the invention is then used for carrying out aided detection, false positive results of serological detection can be effectively removed, so that huge mental stress and property loss brought to the patient can be avoided; meanwhile, aiming at the situation that when the results of detecting the stomach cancer CA19-9, CA24-2 and CEA of the patient by using the sera are negative, and the stomach cancer serological detection and identification kit provided by the invention is then used for carrying out the aided detection,, the false negative results of the serological detection can be effectively found, so that the life of the patient can be rescued in time.

The invention discloses an immunological detection method and a kit for detecting mycobacterium tuberculosis. According to the immunological detection method, mycobacterium tuberculosis specific antigens are adopted. The mycobacterium tuberculosis specific antigens comprise one or two components selected from protein 38kDa, protein CFP10, carbohydrate antigen LAM, and carbohydrate antigen TBGL. According to the invention, a multiple antigen composition is adopted as a mixed antigen for detecting tuberculosis antibodies. The method and the kit have advantages of high sensitivity, high specificity, and low false positive rate. During a real operation process, a multiple point combined determination result is improved into a single point determination result. Therefore the operation is more convenient. With the method and the kit, antibodies in tuberculosis patient body fluid samples such as serum and hydrothorax can be detected specifically in half a day. The kit can be produced in large scale with low cost. Therefore, the invention has an important significance in the controlling of tuberculosis.

The invention relates to the field of liposomal vaccines, and discloses a liposomal vaccine preparation and an application thereof, as well as a method for producing IgG antibodies. The liposomal vaccine preparation comprises: (a) a tumor-associated carbohydrate antigen or glycopeptide antigen; (b) a linking unit; and (c) an adjuvant represented by formulas (1) to (3). According to the technical scheme disclosed by the invention, a high-titer and high-affinity IgG antibody can be guaranteed to be produced while the molecular structure of the vaccine is simplified. In addition, the vaccine molecules are good at thermal stability, thereby being relatively easy to store and transport.

The present invention relates to modifying rapid immunochromatographic (“ICT”) tests for the detection of characteristic carbohydrate antigens of bacteria that are known to be causative of otitis media and respiratory diseases in children under the age of approximately 12 years. Children of this age group are also prone to nasopharyngeal colonization with the same bacteria, and urine samples taken from colonized, but otherwise healthy, children were shown to exhibit an unduly high incidence of test results that were false positive for the presence of disease. The test modifications, which maintain the test sensitivity unchanged and the test specificity at a value above 90% were developed to insure that healthy, albeit colonized, children were not medicated for disease the bacteria are known to cause. The modifications involve either (1) reducing the total amount of antibodies to the carbohydrate antigen employed in each test, (2) adding at least one fixed “scrub” line located just prior to the capture line in the sample flow path to the preprepared ICT test strip to “scrub” out an identical amount of target antigen from all bodily fluid test samples obtained from both colonized but otherwise healthy children and diseased children, or (3) combinations of (1) and (2).

The invention discloses a method for auxiliary diagnosis of liver cancer by means of combined detection of tumor markers based on an artificial neural network. The method comprises the following steps: collecting a blood sample of a patient; adopting a chemiluminesent immunoassay kit to respectively measure the contents of alpha fetoprotein (AFP), carcino-embryonic antigen (CEA) and carbohydrate antigen 125 (CA125) in serum; measuring the level of sialic acid (SA) in the serum by applying a visible spectrophotometry; measuring the level of Ca in the serum by using an azo arsenic III end-point method; carrying out descriptive statistical analysis on all data by using statistics, and taking diagnostic sensitivity, specificity, accuracy, a positive predictive value and a negative predictive value as evaluation indexes; adopting a back-propagation neural network algorithm to obtain a trained model; using the trained model to predict a corresponding test set. The method provided by the invention is high in accuracy rate and can be used for well distinguishing the liver cancer, benign and normal, thus having good popularization and application prospects.

The present invention relates to compositions and methods for treating cancer. The invention makes use of peptides, nucleic acids encoding such peptides, and cells expressing such peptides, where the peptide comprises a tumor-associated carbohydrate antigen (TACA)-binding domain.

The present invention discloses a quantitative determination kit for carbohydrate antigen 125 (CA125). The quantitative determination kit is characterized in that: the kit comprises a CA125 magnetic separation reagent, an enzyme reactant, a reaction reinforcing agent, a diluent, a CA125 standard sample, a CA125 quality control sample, a cleaning solution, a concentrated solution and a substrate solution. The invention further discloses a preparation method for the kit. According to the kit provided by the present invention, a chemiluminescence technology is combined with immunomagnetic nanoparticles; a reaction system approaching to the homogeneous phase is provided; compared to the prior art, the kit provided by the present invention has higher detection sensitivity and higher specificity, and reaches better performance parameters, and the product cost is substantially reduced.

The invention discloses a carbohydrate antigen CA19-9 assay kit. The kit comprises a magnetic separation reagent R1, a labeling reagent R2, a CA19-9 calibration product and a CA19-9 quality control product. The invention also provides a preparation method of the kit. The magnetic separation reagent R1 in the kit is prepared through coupling a CA19-9 monoclonal antibody to the surface of a carboxyl magnetic bead. The labeling reagent R2 is prepared through coupling a luminescent substance acridinium ester to a paired CA19-9 monoclonal antibody. The reactions occur under nearly homogeneous conditions. Through use of an excitation solution, the reaction product antibody-antigen-antibody sandwich complex can immediately release photons at 430 nm and can release strong photons without use of a luminescent enhancer and a catalyst so that luminescence detection can be directly carried out. Through optimizing the experimental processes of magnetic bead coating with an antibody and antibody labeling with acridinium ester, the stability and the detection sensitivity of the kit are greatly improved. The kit has a wide linear detection range, is easy to operate and has a fast detection rate.

The invention discloses a chemiluminescence quantitative detection kit for a carbohydrate antigen 242 (CA242). The kit comprises a CA242 detection reaction plate, an enzyme conjugate, a luminescent substrate, a calibrator, a quality control material and washing concentrate, wherein the reaction plate is coated with a CA242 antibody. The kit can specifically and quantitatively detect the content of the CA242 in patient serum, and is used for the auxiliary diagnosis and prognosis of malignant tumors of a digestive tract such as pancreatic cancer and the like, and monitoring of curative effects. Compared with the conventional enzyme linked immunosorbent assay (ELISA) technology, the chemiluminescence immunoassay keeps high specificity of the ELISA technology, stability and reliability of a detection result, and convenience of operation, and can improve detection sensitivity simultaneously.